U.S. Equities3h ago
Revolution Medicines' Rasonque Wins FDA Nod in Pancreatic Cancer
Daraxonrasib cleared 6.5 months early with Phase 3 data showing median 13.2-month survival versus 6.7 months on chemotherapy in second-line metastatic pancreatic cancer.